- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03809858
Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses
18 april 2020 uppdaterad av: Marc Breton, University of Virginia
Pilot Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses
This will be a randomized, cross-over, unblinded study with subjects randomized upon entry into the study to either begin using the Klue software for 6 weeks or to continue with their usual care for 6 weeks.
Subjects are eligible for enrollment if they are using a continuous glucose monitor (CGM) with an insulin pump or an insulin pen with memory, and are missing or late in giving at least 4 food boluses in the previous two weeks.
Missing or late meal boluses will be assessed through their pump/pen and sensor downloads.
This is a pilot study.
There is no preliminary data to do a true power calculation.
The primary outcome will be the change in the number of missed meal boluses in the two weeks prior to each visit.
Secondary outcome measures will be the number of missed meal boluses in each month of the study, change in HbA1c levels (measured every 6 weeks), accuracy of the Klue software in detecting meals (true positive and false positive rates), and a user satisfaction survey.
Studieöversikt
Studietyp
Interventionell
Inskrivning (Faktisk)
12
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- University of Virginia
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Age 18 and over
- Using an insulin pump for at least 3 months and currently using CGM or using an insulin pen with memory and currently using a CGM
- Willing to wear a CGM at least 70% of the time while in the study
- Willing to wear an Apple watch on their dominant hand while awake
- Missing or late in giving at least four food boluses in the previous 2 weeks
- Understanding and willingness to follow the protocol and sign informed consent
Exclusion Criteria:
- Pregnant or lactating women
- A known medical condition that in the judgement of the investigator might interfere with the completion of the protocol Note: Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment.
- Current treatment for a seizure disorder
- Inpatient psychiatric treatment in the past 6 months
Subject may participate in another trial if it is approved by the investigators of both trials.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Klue App Use then Usual Care
Subjects will use the Klue App during the first 6 weeks of the trial.
At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
|
The Klue App utilizes an Apple Watch to detect eating or drinking behavior.
The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
|
|
Experimentell: Usual Care then Klue App Use
Subjects will begin the study without using the Klue App during the first 6 weeks of the trial.
At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
|
The Klue App utilizes an Apple Watch to detect eating or drinking behavior.
The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of missed meal boluses
Tidsram: During the two weeks prior to each visit
|
The change in the number of missed meal boluses
|
During the two weeks prior to each visit
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of missed meal boluses as a measure of attenuation to the alerts
Tidsram: 6 weeks
|
The change in the number of missed meal boluses as a measure of attenuation to the alerts
|
6 weeks
|
|
Number of missed meal boluses as a measure of attenuation to the alerts
Tidsram: 12 weeks
|
The change in the number of missed meal boluses as a measure of attenuation to the alerts
|
12 weeks
|
|
Change in Hemoglobin A1c Levels
Tidsram: 3 months
|
Change in Hemoglobin A1c Levels
|
3 months
|
|
Time in range 70-180 mg/dL
Tidsram: 6 weeks
|
Time in range 70-180 mg/dL as measured by CGM
|
6 weeks
|
|
Time in range 70-180 mg/dL
Tidsram: 12 weeks
|
Time in range 70-180 mg/dL as measured by CGM
|
12 weeks
|
|
Percent time <70 mg/dL mean glucose
Tidsram: 6 weeks
|
Percent time <70 mg/dL mean glucose as measured by CGM
|
6 weeks
|
|
Percent time <70 mg/dL mean glucose
Tidsram: 12 weeks
|
Percent time <70 mg/dL mean glucose as measured by CGM
|
12 weeks
|
|
Glucose Coefficient of Variation
Tidsram: 6 weeks
|
Glucose (as measured by CGM) Coefficient of Variation
|
6 weeks
|
|
Glucose Coefficient of Variation
Tidsram: 12 weeks
|
Glucose (as measured by CGM) Coefficient of Variation
|
12 weeks
|
|
Total daily insulin dose
Tidsram: 6 weeks
|
Total daily insulin dose
|
6 weeks
|
|
Total daily insulin dose
Tidsram: 12 weeks
|
Total daily insulin dose
|
12 weeks
|
|
Number of meal bolus injections each day
Tidsram: 6 weeks
|
Number of meal bolus injections each day
|
6 weeks
|
|
Number of meal bolus injections each day
Tidsram: 12 weeks
|
Number of meal bolus injections each day
|
12 weeks
|
|
Number of total bolus injections each day
Tidsram: 6 weeks
|
Number of total bolus injections each day
|
6 weeks
|
|
Number of total bolus injections each day
Tidsram: 12 weeks
|
Number of total bolus injections each day
|
12 weeks
|
|
Total daily basal insulin
Tidsram: 6 weeks
|
Total daily basal insulin
|
6 weeks
|
|
Total daily basal insulin
Tidsram: 12 weeks
|
Total daily basal insulin
|
12 weeks
|
|
Accuracy of Klue in detecting meals
Tidsram: 3 months
|
Accuracy of Klue in detecting meals (true positive and false positive rates)
|
3 months
|
|
User satisfaction of Klue
Tidsram: 3 months
|
User satisfaction of Klue
|
3 months
|
|
Diabetes-Specific Attitudes about Technology (DSAT) Scores
Tidsram: 3 months
|
DSAT Scores (Scaled from "Strongly Disagree" to "Strongly Agree" in relation to attitudes related to technology in diabetes treatment)
|
3 months
|
|
Diabetes Distress Scale (DDS) Scores
Tidsram: 3 months
|
DDS Scores (Scaled from "Not a Problem" to "A Very Serious Problem" in relation to feelings/mood related to diabetes)
|
3 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Marc Breton, PhD, University of Virginia
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, Klingensmith GJ. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004 Mar;113(3 Pt 1):e221-4. doi: 10.1542/peds.113.3.e221.
- Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes. 2009 Apr;10(2):142-8. doi: 10.1111/j.1399-5448.2008.00462.x. Epub 2008 Oct 24.
- O'Connell MA, Donath S, Cameron FJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes. 2011 Sep;12(6):556-9. doi: 10.1111/j.1399-5448.2010.00740.x. Epub 2011 Apr 6.
- Naranjo D, Tanenbaum ML, Iturralde E, Hood KK. Diabetes Technology: Uptake, Outcomes, Barriers, and the Intersection With Distress. J Diabetes Sci Technol. 2016 Jun 28;10(4):852-8. doi: 10.1177/1932296816650900. Print 2016 Jul.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
29 maj 2019
Primärt slutförande (Faktisk)
18 november 2019
Avslutad studie (Faktisk)
18 november 2019
Studieregistreringsdatum
Först inskickad
11 januari 2019
Först inskickad som uppfyllde QC-kriterierna
15 januari 2019
Första postat (Faktisk)
18 januari 2019
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
21 april 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
18 april 2020
Senast verifierad
1 april 2020
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 180034
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
IPD-planbeskrivning
There is no current plan to share individual participant data
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus, typ 1
-
Superior UniversityAktiv, inte rekryterandeTyp 2-diabetes mellitus 1Pakistan
-
COUR Pharmaceutical Development Company, Inc.RekryteringTyp 1-diabetes | Typ 1-diabetes mellitus | T1DM | T1D | Typ 1-diabetes i tonåren | Typ 1-diabetes hos barn | Typ 1-diabetespatienter | Typ 1 diabetes mellit | T1DM - Typ 1-diabetes mellitus | Typ 1-diabetes (juvenil debut)Förenta staterna
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's...RekryteringTyp 1-diabetes mellitus | T1DM | Typ 1-diabetes mellitus (T1DM) | T1DM - Typ 1-diabetes mellitusIrak, Pakistan
-
Lund UniversityAnmälan via inbjudanTyp 1-diabetes mellitus | Steg 2 Typ 1-diabetes | Steg 1 Typ 1-diabetes | Steg 3 Typ 1-diabetesSverige
-
Assiut UniversityHar inte rekryterat ännuDiabtes mellitus typ 1
-
Medical College of WisconsinHar inte rekryterat ännuTyp 1-diabetes | Typ 1-diabetes mellitus | typ 1 diabetes | Icke-näringsrik sötningsmedelFörenta staterna
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Diabetes typ 1 | Typ 1-diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinberoende | Ungdomsdiabetes | Diabetes, autoimmun | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | Diabetes mellitus, spröd | Diabetes mellitus, juvenil-debut och andra villkorFörenta staterna
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAvslutadTyp 1-diabetes mellitus | Diabetes mellitus, typ I | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | IDDMFörenta staterna, Australien
-
Capillary Biomedical, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Typ 1-diabetes mellitus | Diabetes mellitus, insulinberoende, 1Australien
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
Kliniska prövningar på Klue App
-
Medtronic DiabetesAvslutad
-
The University of Hong KongHar inte rekryterat ännuDigital hälsa | Knäsmärta/ArtrosHong Kong
-
New York UniversityJoon, Inc.RekryteringDepression | Påfrestning | Ångest | Exekutiv dysfunktion | Beteende, barn | Störande beteende | UppmärksamhetsbristFörenta staterna
-
London School of Hygiene and Tropical MedicineAvslutadNäring | Hållbarhet | Mobile Health Technology (mHealth)Storbritannien
-
CEU San Pablo UniversityAvslutad
-
Institute for Human Development and Potential (IHDP)...Aktiv, inte rekryterandeDiabetes typ 2 | Graviditetsdiabetes | Hälsosamma livsstilsbeteendenSingapore
-
Fundación de Investigación Biomédica - Hospital...Fundación para la investigación biomética Hospital Infantil Universitario...Rekrytering
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Stanford...AvslutadFysisk aktivitetFörenta staterna
-
Klein Buendel, Inc.Pennington Biomedical Research CenterAvslutadSömnbrist | Övervikt och fetma | HälsobeteendeFörenta staterna
-
Arizona State UniversityPhoenix VA Health Care SystemAvslutad